drugset
drugset / Trial / NCT03833700

A Study of E7386 in Participants With Advanced Solid Tumor Including Colorectal Cancer (CRC)

NCT03833700 ↗

Phase 1 Active not recruiting 70 enrolled Eisai Inc.
Non-randomizedSequentialOpen-labelTreatment

Summary

This study will be conducted to assess the safety and tolerability of E7386 in participants with solid tumor including CRC.

Timeline

Start
2019-03-05
Primary completion
2027-03-31
Completion
2027-03-31

Drugs

EvaluationDrugModalityDoseRoute
Subject E7386 Small molecule — —

Indications

colorectal neoplasm